ClinicalTrials.gg
Not yet recruitingNCT07392125ORCA-V2Updated Feb 6, 2026

Phase 3 Trial Evaluating the Efficacy and Safety of Cytisinicline for Vaping Cessation in Adults Using Nicotine-Containing E Cigarettes

A Phase 3 interventional study of Cytisinicline and Placebo in Vaping Cessation, sponsored by Achieve Life Sciences. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-06.

Sponsored by Achieve Life Sciences · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
800
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This will be a multi-center, double-blind, randomized, placebo-controlled, Phase 3 study conducted in male or female adults who are daily nicotine e-cigarette users only.

A total of approximately 800 subjects will be randomly assigned (1:1) to one of two Arms:

  • Arm B, 12 weeks cytisinicline + behavior support: N=400 or
  • Arm A, 12 weeks of placebo+ behavior support: N=400) The primary objective is to assess whether subjects randomized to Arm B (3 mg cytisinicline TID for 12 weeks plus behavioral support) have a higher probability of nicotine vaping cessation from Week 9 to Week 12 as compared to subjects randomized to Arm A (placebo TID for 12 weeks plus behavioral support).
02

Conditions studied

  • Vaping Cessation

Browse trials for

Keywords

  • vaping cessation
03

In context

Vaping

403 studies on the registry are indexed under Vaping; 96 are open to participants now.

This study's planned enrollment of 800 is above the median of 80 across 323 interventional studies indexed under Vaping.

Browse Vaping studies →

Lead sponsor

Achieve Life Sciences is the lead sponsor of 31 studies on the registry; 1 is open to participants now.

Of its 12 completed or terminated interventional studies of FDA-regulated products, 8 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects, age ≥18 years.
  • Test positive for cotinine using a point-of-care Oral Fluid Screening Device (OFD) with positive detection at ≥30 ng/mL cotinine.
  • Current daily nicotine-containing electronic cigarette usage as recorded in a screening diary for at least 7 consecutive days. Willing to bring the e-cigarette or nicotine device used to the clinical site so that the specific product type, flavor, and nicotine level can be documented.
  • Failed at least one previous attempt to stop vaping with or without therapeutic support.
  • Willing to initiate study treatment on the day after randomization and set a quit date within Day 7 and Day 14.
  • Willing to actively participate in the study's vaping cessation behavioral support provided throughout the study.
  • Able to fully understand study requirements, willing to participate, and comply with dosing schedule.
  • Sign the Form.

Exclusion criteria

Exclusion Criteria:

  • Currently smoking or having smoked within 3 months prior to study randomization, any combustible cigarettes, other combustible tobacco products or non-combustible tobacco products such as heat not burn products or nicotine pouches (ie, dual users).
  • Currently smoking/vaping cannabis or having smoked or vaped cannabis within 4 weeks (28 days) prior to study randomization or planned use while on study. Other methods of cannabis consumption, eg, edibles, tinctures, capsules, topicals, etc. are allowed.
  • Expired Carbon Monoxide (CO) levels ≥6 ppm, indicating recent combustible tobacco or cannabis smoking.
  • A score of 0-3 on the Penn State e-Cigarette Dependence Index indicating no dependence.
  • More than 1 study subject in same household during the study treatment period.
  • Known to any of the , previous cytisinicline treatment in a prior clinical study, or any previous use of cytisinicline.
  • Positive urinary drugs of abuse screen determined within 28 days before the first dose of study drug. (Note: Although THC is part of the standard drug screen, it is not necessarily exclusionary. Refer to exclusion criteria #2).
  • abnormal serum chemistry or hematology values, as determined by the investigator, within 28 days of randomization.
  • Clinically significant abnormalities on screening visit 12-lead , as determined by the investigator, after minimum of 5 minutes in supine position within 28 days of randomization.
  • Recent history (within 3 months prior to screening) of acute myocardial infarction, unstable angina, stroke, cerebrovascular incident or hospitalization for congestive heart failure.
  • Current uncontrolled hypertension (systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg).
  • Currently psychotic or having had a psychotic event in the 3 months prior to the screening visit. If any subject becomes psychotic during the study, they must be removed from treatment and/or additional study visits.
  • Currently having suicidal ideation or risk for suicide (YES to either question 3, 4 or 5 OR YES to any suicidal behavior question on the C-SSRS with clear suicidal intent or suicide attempt within the last 10 years).
  • Current symptoms of moderate to severe depression (depression score ≥11 using depression questions on the Hospital Anxiety and Depression Scale [HADS] at screening visit).
  • Renal impairment defined as a (CrCl) \<60 mL/min at screening visit (estimated with the Cockroft-Gault equation and reported by the central laboratory).
  • Hepatic impairment defined as (ALT) or aspartate aminotransferase (AST) >2.0 x the (ULN) at screening visit.
  • Recent history or symptoms (within 4 weeks of randomization) of unstable respiratory disease (eg, pneumonia, product-use associated lung injury or EVALI, etc).
  • Women who are pregnant or breast-feeding.
  • Female subjects of who do not agree to use acceptable methods of during the study. Acceptable methods of birth control include:
  • True abstinence: When this is in line with the preferred and usual lifestyle of the subject. [Periodic abstinence (eg, calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception].
  • Barrier methods:
  • diaphragm
  • cervical cap
  • contraceptive sponge
  • intrauterine device (IUD)
  • double barrier method (condom with spermicide)
  • Hormonal methods:
  • Oral contraceptives
  • Vaginal ring such as NuvaRing
  • Skin patch such as Xulane
  • Injection such as Depro-Provera
  • Implantable rod such as Nexplanon
  • Intrauterine device (IUD)
  • Participation in a clinical study with an drug or biologic in the 4 weeks prior to study randomization.
  • Use of any smoking cessation medications (bupropion, varenicline, nortriptyline, or any nicotine replacement therapy [NRT]) in the 4 weeks prior to study randomization or planned use of these or other nicotine replacement medications during the study.
  • Any planned use during the study of combustible cigarettes or other nicotine-containing, non-vaping products (eg, pipe tobacco, cigars, snuff, smokeless tobacco, hookah, ZYN pouches, etc).
  • Any other reason that the investigator views the subject should not participate or would be unable to fulfill the requirements for the study.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
800 participants (estimated)

Study arms

  • Placebo comparator
    Arm A

    12 weeks of placebo + behavioral support; 400 subjects

    Drug: Placebo · Behavioral: Behavioral Support

  • Active comparator
    Arm B

    12 weeks cytisinicline + behavioral support; 400 subjects

    Drug: Cytisinicline · Behavioral: Behavioral Support

Interventions

  • Tablet, 3 times a day (TID), 12 weeks

    Also known as: cytisine

  • DrugPlacebo

    Tablet, 3 times a day (TID), 12 weeks

  • BehavioralBehavioral Support

    16 behavioral support sessions, starting prior to randomization and through Week 12, 3 additional sessions during the follow-up period.

06

What researchers measure

Primary outcomes

  1. Primary Efficacy Objective

    Assess whether subjects randomized to Arm B (3 mg cytisinicline TID for 12 weeks plus behavioral support) have a higher probability of nicotine vaping cessation from Week 9 to Week 12 post-randomization as compared to subjects randomized to Arm A (placebo TID for 12 weeks plus behavioral support). Successful vaping cessation is defined as weekly vaping abstinence during the last 4 weeks of the 12-week treatment period (Week 9 through Week 12) using quantitative cotinine levels at \<10 ng/mL for biochemical verification and subject's self-report of no vaping using a daily electronic diary

    Time frame: Randomization to Week 24 follow-up visit

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for May 2026; primary completion for Nov 2026, 6 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2026
First posted
Feb 6, 2026
StartEst.
May 15, 2026
Primary completionEst.
Nov 15, 2026
CompletionEst.
Sep 30, 2027
Last update
Feb 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07392125
Responsible party
Sponsor
First posted
Feb 6, 2026
Start date
May 15, 2026 (estimated)
Primary completion
Nov 15, 2026 (estimated)
Completion
Sep 30, 2027 (estimated)
Last update
Feb 6, 2026

Study contacts

Julie Ball; Vice President, Clinical Operations
Contact
jball@achievelifesciences.com
425-686-1540
Roxann Becco; Sr. Director, Clinical Operations
Contact
rbecco@achievelifesciences.com
312-288-1187
Julie Ball
study director · Achieve Life Sciences, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cytisine

Start the discussion